ArticlePLoS neglected tropical diseases2013
Arginase activity in the blood of patients with visceral leishmaniasis and HIV infection.
Article in PLoS neglected tropical diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Systematic review of biomarkers to monitor therapeutic response in leishmaniasis.Antimicrobial agents and chemotherapy · 2015Pooled it
- Therapeutic Modulation of Arginase with nor-NOHA Alters Immune Responses in Experimental Mouse Models of Pulmonary Tuberculosis including in the Setting of Human Immunodeficiency Virus (HIV) Co-Infection.Tropical medicine and infectious disease · 2024Article
- Engineering metabolism to modulate immunity.Advanced drug delivery reviews · 2024Review
- Optimization of the arginase activity assay micromethod for macrophages and sera.BMC research notes · 2023Article
- Article
- Immunological factors, but not clinical features, predict visceral leishmaniasis relapse in patients co-infected with HIV.Cell reports. Medicine · 2022Article
- Potential biomarkers of immune protection in human leishmaniasis.Medical microbiology and immunology · 2021Review
- Post kala-azar dermal leishmaniasis: A threat to elimination program.PLoS neglected tropical diseases · 2020Review
- T cell suppression in the bone marrow of visceral leishmaniasis patients: impact of parasite load.Clinical and experimental immunology · 2018Article
- Arginase-1 Is Responsible for IL-13-Mediated Susceptibility toFrontiers in immunology · 2018Article
- Effect of iron-folic acid supplementation on change of hemoglobin among visceral Leishmaniasis patients in northwest Ethiopia: a retrospective follow up study.BMC hematology · 2018Article
- Trypanosomatid Infections: How Do Parasites and Their Excreted-Secreted Factors Modulate the Inducible Metabolism of l-Arginine in Macrophages?Frontiers in immunology · 2018Review
- Metabolic Modulation in Macrophage Effector Function.Frontiers in immunology · 2018Review
- Modulation of Immune Signaling and Metabolism Highlights Host and Fungal Transcriptional Responses in Mouse Models of Invasive Pulmonary Aspergillosis.Scientific reports · 2017Article
- Human Neutrophil Peptide 1 as immunotherapeutic agent against Leishmania infected BALB/c mice.PLoS neglected tropical diseases · 2017Article
- Leptin regulates Granzyme-A, PD-1 and CTLA-4 expression in T cell to control visceral leishmaniasis in BALB/c Mice.Scientific reports · 2017Article
- Disease severity in patients with visceral leishmaniasis is not altered by co-infection with intestinal parasites.PLoS neglected tropical diseases · 2017Article
- Arginase activity in pathogenic and non-pathogenic species of Leishmania parasites.PLoS neglected tropical diseases · 2017Article
- l-Arginine Uptake by Cationic Amino Acid Transporter Promotes Intra-Macrophage Survival ofFrontiers in immunology · 2017Article
- A Subset of Neutrophils Expressing Markers of Antigen-Presenting Cells in Human Visceral Leishmaniasis.The Journal of infectious diseases · 2016Article
Corrections and comments
- Erratum issued
Authors and funding
15 authors at 7 institutions in 4 countries.
Funding
Abstract
backgroundVisceral leishmaniasis is a parasitic disease associated with high mortality. The most important foci of visceral leishmaniasis in Ethiopia are in the Northwest and are predominantly associated with high rates of HIV co-infection. Co-infection of visceral leishmaniasis patients with HIV results in higher mortality, treatment failure and relapse. We have previously shown that arginase, an enzyme associated with immunosuppression, was increased in patients with visceral leishmaniasis and in HIV seropositive patients; further our results showed that high arginase activity is a marker of disease severity. Here, we tested the hypothesis that increased arginase activities associated with visceral leishmaniasis and HIV infections synergize in patients co-infected with both pathogens. METHODOLOGY/PRINCIPAL
findingsWe recruited a cohort of patients with visceral leishmaniasis and a cohort of patients with visceral leishmaniasis and HIV infection from Gondar, Northwest Ethiopia, and recorded and compared their clinical data. Further, we measured the levels of arginase activity in the blood of these patients and identified the phenotype of arginase-expressing cells. Our results show that CD4(+) T cell counts were significantly lower and the parasite load in the spleen was significantly higher in co-infected patients. Moreover, our results demonstrate that arginase activity was significantly higher in peripheral blood mononuclear cells and plasma of co-infected patients. Finally, we identified the cells-expressing arginase in the PBMCs as low-density granulocytes.
conclusionOur results suggest that increased arginase might contribute to the poor disease outcome characteristic of patients with visceral leishmaniasis and HIV co-infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.